Research programme: chimeric immunomodulatory DNA - Dynavax

Drug Profile

Research programme: chimeric immunomodulatory DNA - Dynavax

Alternative Names: Chimeric immunomodulatory compounds - Dynavax; Chimeric immunomodulatory oligonucleotides - Dynavax; CIC - Dynavax

Latest Information Update: 16 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Class Oligonucleotides
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Viral infections

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 16 Apr 2008 Discontinued - Preclinical for Viral infections in USA (unspecified route)
  • 25 Sep 2006 Chimeric immunomodulatory DNA compounds are still in preclinical trials in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top